Figure 1 Exosomes with siRNAs targeting

Slides:

Advertisements

Similar presentations

Figure 4 PET imaging in experimental pancreatic cancer

Advertisements

Figure 2 Exosome composition

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Cellular processes involved in cancer development

Figure 1 Contribution of the gut microbiota

Figure 4 Activation of clopidogrel via cytochrome P450

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 6 Injection of mesenchymal stem cells in perianal fistulas

Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 1 Suppression of SLC22A3 and A-to-I editing

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 7 Clinical options for HCC therapy

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 5 Exosomes for delivery of RNA interference therapeutics

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 Towards precision PRRT for neuroendocrine tumours

Figure 3 The 'leaky gut' hypothesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 A schematic representation of the HER2 signalling pathway

Figure 4 Tumour-induced neutrophil extracellular trap

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 The association between CD8+ T‑cell density of the tumour

Figure 2 Modelling the effect of HCV treatment on reinfection in people who inject drugs Figure 2 | Modelling the effect of HCV treatment on reinfection.

Figure 4 Proinflammatory immune cells and their crosstalk in patients with IBD Figure 4 | Proinflammatory immune cells and their crosstalk in patients.

Figure 1 Functions, features and phenotypes of HSCs in normal and diseased livers Figure 1 | Functions, features and phenotypes of HSCs in normal and diseased.

Figure 4 Oncogenic KRAS and inflammation

Figure 2 Switching of biologic agents and biosimilars

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Macrophage-targeting antitumour treatment approaches

Figure 1 Overview of the immunopathogenesis of ulcerative colitis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

An overview of oncogenic KRAS-driven RAF/MEK/ERK and PI3K/PDK1/AKT signalling networks in pancreatic cancer Figure 1 from Eser et al. British Journal.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

to the liver and promote patient-derived xenograft tumour growth

Figure 7 Example colonic high-resolution manometry

Figure 1 Environmental factors contributing to IBD pathogenesis

Figure 1 Median coverage and distribution by

Figure 3 Serotonin influences many peripheral tissues

in the UK (1961–2012), France (1961–2014) and Italy (1961–2010)

Figure 5 Chrononutrition in the liver

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 The role of CTLA4 and PD1 in T cell activation

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Schematic of normal and abnormal liver regeneration

Figure 1 Animal models of liver regeneration

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 Strategies to improve liver regeneration

Roles for KRAS in Pancreatic Tumor Development and Progression

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 3 KRAS-driven intrinsic signalling pathways

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 4 Role of exosomes in the pathogenesis of alcoholic hepatitis

Figure 1 Cancer stem cell plasticity and stem cell homeostasis in the gut Figure 1 | Cancer stem cell plasticity and stem cell homeostasis in the gut.

Figure 2 Biologics that target CD4+ T helper (TH)-cell subsets

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 1 New therapeutic approaches in IBD therapy based on blockade of T-cell homing and retention Figure 1 | New therapeutic approaches in IBD therapy.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Figure 2 Lifelong influences on the gut microbiome from

Figure 1 NAFLD pathogenesis

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Fig. 3. Inactivation of the Wnt/β-catenin signaling pathway inhibited cell proliferation and induced apoptosis in A549 and SPC-A-1 cells. Inactivation.

Figure 1 The spread of colorectal cancer metastases

Wild-type and oncogenic Ras differentially regulate cell proliferation

Presentation transcript:

Figure 1 Exosomes with siRNAs targeting the KRASG12D oncogene in experimental pancreatic cancer models Figure 1 | Exosomes with siRNAs targeting the KRASG12D oncogene in experimental pancreatic cancer models. Purified exosomes from normal human foreskin fibroblasts are loaded with small interfering RNA (siRNA) or short hairpin RNA that silences KRASG12D (forming iExosomes) (1). iExosomes containing CD47 have limited clearance in the circulation (phagocytosis by monocytes is prevented) compared with CD47− iExosomes and iLiposomes (serving as controls) (2). Pancreatic cancer cells uptake iExosomes via macropinocytosis (3). siRNA targeting KRASG12D reduces KRAS GTPase activity and downstream activation of RAF–MEK–ERK or PI3K–AKT–mTOR signalling, inhibits cell proliferation and increases pancreatic cancer cell apoptosis (4). iExosomes injected intraperitoneally are preferentially taken up by pancreatic cancer cells, and markedly inhibit tumour growth and metastatic progression (5). Buscail, L. (2017) Exosomes for targeting KRAS in the treatment of pancreatic cancer Nat. Rev. Gastroenterol. Hepatol. doi:10.1038/nrgastro.2017.113